Evidence map›Paper›PMID 41158823›Full record

ReviewThe Lancet regional health. Western Pacific2025

Pediatric MASLD in China: epidemiology, screening, diagnosis, and management.

Xiaoguo Li, Xiao-Dong Zhou, Jie Wu, Zhenhua Zhao, Feng Xie, Yiling Li, Wenhui Li, Xiaosong Yan, Sumin Sui, Liting Zhang and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiaoguo LiLiver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Nanjing, China.
Xiao-Dong ZhouMAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jie WuDepartment of Gastroenterology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Zhenhua ZhaoDepartment of Radiology, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing, China.
Feng XieFunctional Inspection Center, Lanzhou Maternal and Child Health Care Hospital, Lanzhou, China.
Yiling LiGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Wenhui LiDepartment of Hospital Administration, Yancheng Maternal and Child Health Care Hospital Affiliated to Yangzhou University, Yancheng, China.
Xiaosong YanDepartment of Surgery, Third People's Hospital of Tibet, Lhasa, China.
Sumin SuiDepartment of Pediatric, The People's Hospital of Bozhou, Bozhou, China.
Liting ZhangDepartment of Hepatology, First Hospital of Lanzhou University, Lanzhou, China.
Ming-Hua ZhengMAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yuemin NanDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, China.
Xiaolong QiLiver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global epidemic, with a rapidly increasing burden among children and adolescents in China. This alarming trend is primarily driven by profound lifestyle shifts. Unlike earlier perceptions of pediatric MASLD as relatively benign, pediatric-onset MASLD is now recognized as a progressive condition associated with liver fibrosis, cirrhosis, cardiometabolic comorbidities, and elevated risks of hepatocellular carcinoma and early mortality. In China, this escalating burden is compounded by regional disparities, diagnostic challenges, and limited access to pediatric-specific screening and management tools. Yet early-life detection and intervention present a critical window to mitigate long-term liver-related and systemic health consequences. This review synthesizes the latest epidemiological data, screening strategies, diagnostic innovations, and therapeutic approaches for pediatric MASLD in the Chinese context. By integrating emerging evidence with national public health priorities, we aim to inform actionable policies and tailored intervention strategies to confront this growing epidemic.

Indexed as

Childhood obesityEpidemiology in ChinaLifestyle interventionliver steatosisNon-invasive screeningPediatric metabolic dysfunction-associated steatotic liver disease

Identifiers

PMID41158823
PMCPMC12556317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.